UNITED THERAPEUTICS Corp business relationships

“In the United States, we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty.” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

“Adcirca is shipped to customers in accordance with purchase orders received by Lilly.” SEC filing

“We sell Adcirca under an in-license from Lilly that expires December 31, 2026.” SEC filing

“Adcirca is manufactured for us by Lilly and distributed through its pharmaceutical wholesaler network on our behalf.” SEC filing

“We distribute Unituxin in the United States through an exclusive distribution agreement with Cencora Global Procurement Ltd ( Cencora ).” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

“Our U.S. patents for Orenitram orally administered formulations, controlled moisture storage and manufacturing methods, as well as those covering controlled release formulations licensed to us by Supernus Pharmaceuticals Inc. ( Supernus ).” SEC filing

“We pay a ten percent royalty on our net sales of Tyvaso DPI under our license agreement with MannKind.” SEC filing

“In February 2021, we launched commercial sales of the Remunity Pump, which is a semi-disposable system for subcutaneous delivery of treprostinil that we developed in collaboration with DEKA Research & Development Corp. ( DEKA ) under an exclusive development and license agreement.” SEC filing

“First Amendment to License and Collaboration Agreement, dated August 24, 2025 between the Registrant and MannKind Corporation, incorporated by reference to Exhibit 10.” SEC filing

“In November 2019, we entered into a supply agreement with an affiliate of DEKA Research & Development Corporation ( DEKA ) to manufacture and supply the Remunity ® Pump to us.” SEC filing

“Pursuant to the Supply Agreement, MannKind is responsible for manufacturing and supplying Tyvaso DPI to us.” SEC filing

“On October 2, 2024, Liquidia and Pharmosa announced that they amended the licensing agreement to expand Liquidia's licensed territory to include Europe, Japan, and elsewhere, and to include rights to Pharmosa's nebulizers for use with L606.” SEC filing

“ICU Medical discontinued manufacturing the MS-3 system used to administer subcutaneous Remodulin, and specialty pharmacy distributors informed us that supplies of MS-3 pumps are exhausted, although a limited number of refurbished pumps may be available for use with generic treprostinil.” SEC filing

“United Therapeutics License Agreement - In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the "UT License Agreement"), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI...” SEC filing

“Our development and marketing partner (sometimes referred to as our collaboration partner), United Therapeutics Corporation ("United Therapeutics" or "UT") began commercializing Tyvaso DPI in June 2022 and is obligated to pay us a royalty on net sales of the product.” SEC filing

“Because United Therapeutics is solely responsible for the development, marketing, promotion, and sale of Tyvaso DPI, our ability to maintain and grow this revenue is highly dependent on the commercial performance of Tyvaso DPI and on United Therapeutics' strategic priorities, resource allocation dec...” SEC filing

“| | ● | | IP-agonists to treat PAH , such as selexipag, marketed by Actelion, and ralinepag, licensed from Arena Pharmaceuticals, Inc. by United Therapeutics, which is currently in Phase 3 clinical development with positive top-line results announced in March 2026. |” SEC filing

“Branded pharmaceutical companies such as United Therapeutics continue to defend their products vigorously through, among other actions, life cycle management, marketing agreements with third-party payors, pharmacy benefits managers and generic manufacturers.” SEC filing

“Customers including United Therapeutics, Metro Aviation and New Zealand Air Ambulance have placed Firm Orders for BETA aircraft.” SEC filing

“Our partners and customers include UPS, with whom we collaborate to design systems for the efficient movement of cargo, and United Therapeutics for specialized organ transport.” SEC filing